Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Rua BioscienceNZSE:RUA +2.50% EV-to-FCF is -5.88 as of Aug. 02, 2026. The stock has 4 warning signs investors should review. Among 571 Drug Manufacturers companies, Rua Bioscience ranks worse than 175131.17% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rua Bioscience's Enterprise Value is NZ$13.51 Mil.
Rua Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-2.30 Mil. Therefore, Rua Bioscience's EV-to-FCF for today is -5.88.
The historical rank and industry rank for Rua Bioscience's EV-to-FCF or its related term are showing as below:
NZSE:RUA'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.44 Med: -1.95 Max: 0.01
Current: -5.44
During the past 5 years, the highest EV-to-FCF of Rua Bioscience was 0.01. The lowest was -5.44. And the median was -1.95.
NZSE:RUA's EV-to-FCF is ranked worse than 100% of 571
companies
in the Drug Manufacturers industry
Industry Median: 20.66
vs NZSE:RUA: -5.44
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rua Bioscience's PE Ratio (TTM) for today is calculated as:
Rua Bioscience's share price for today is NZ$0.041.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-0.015.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Rua Bioscience EV-to-FCF Related Terms
Rua Bioscience EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Rua Bioscience's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Rua Bioscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rua Bioscience EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Rua Bioscience's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rua Bioscience's EV-to-FCF falls into.
Rua Bioscience's current Enterprise Value is NZ$13.51 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Rua Bioscience's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was NZ$-2.30 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rua Bioscience (NZSE:RUA) has a EV-to-FCF of -5.88 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rua Bioscience and its competitors. According to the industry distribution chart, Rua Bioscience ranks #999999 out of 571 companies in the Drug Manufacturers industry.
Is Rua Bioscience's EV-to-FCF too high?
Rua Bioscience's current EV-to-FCF is -5.88. Based on the distribution chart, Rua Bioscience ranks #999999 out of 571 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Rua Bioscience's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Rua Bioscience ranks #999999 out of 571 companies for EV-to-FCF. This places Rua Bioscience in the lower half of its industry. The industry median EV-to-FCF is 20.66. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.66, based on 571 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rua Bioscience and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rua Bioscience's current EV-to-FCF is -5.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rua Bioscience stock overvalued right now?
Rua Bioscience (NZSE:RUA) has a current EV-to-FCF of -5.88. The current EV-to-FCF is -5.88. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Rua Bioscience (NZSE:RUA), the current EV-to-FCF is -5.88 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rua Bioscience Ltd is a pharmaceutical company engaged in the production of cannabinoid medicines. The company caters to both domestic and international customers. It operates in one segment, being research and development and the sale of pharmaceutical products in Australia, Germany, and New Zealand.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NZSE:RUA has been successfully added to your 
